CM Hospitalar SA

CM Hospitalar SA

VVEO3 · SA · Healthcare / Medical Distribution

0.56BRL-0.01 (-1.75%)

Price History

Full chart

Market Stats

Previous Close0.57
Open0.59
Day Range0.56 – 0.59
52-Week Range0.56 – 1.86
Volume1.17M
Market Cap268.55M
P/E (TTM)4.72
Forward P/E12.82
EPS0.18
Dividend Yield0.00%
Beta0.62
50-Day Avg0.717
200-Day Avg1.14

About

CM Hospitalar S/A engages in the distribution of hospital materials, medicines, and nutrition products in Brazil. The company offers material products for cardiac, surgical, urinary, diagnosis, sterilization, wound management, hygiene and protection, infusion, clinical nutrition, orthopedic, and respiratory; and medications, such as painkillers, anesthetics, anti-allergy, antibiotics, antiemetics, antifungals, anti-inflammatory, special control, several, and oncology. It also provides materials for respiratory assistance, therapy, anti-inflammatories, anti-tnf, antacid, antiandrogens, antianemics, anti-asthmatics, antibiotics, anticoagulant, anticonvulsant, monoclonal antibody, anti-growth, antidepressants, antidiabetic drug, antidiuretics, antidote, antiemetics and antinauseants, anti-migraine, antiepileptics, antiestrogens, antifibrinolytics, antiflatulents, antifungals, antihemorrhagic drug, antimicrobial, antineoplastics, antiparathyroid, antiparkinsonian, antipsychotics, systemic antipsoriasis, antirheumatic drugs, anti-varicose, antivirals, beta-blockers, carbohydrate, cycloplegic, contraceptives, contrast, special control, corticosteroids, topical debriding agent, diuretics, several, electrolyte, pancreatic enzyme, erythropoietins, uterine stimulant, cardiac stimulators, growth factor, granulocyte colony stimulating factor, gastroprokinetics, systemic hemostatics, heparins, hepatoprotective and lipotropic agents, hormone, adenohypophyseal hormones, growth hormones, immunoglobulins, immunosuppressants, labor induction drugs, proton pump inhibitor, phosphodiesterase and bone resorption inhibitor, platelet aggregation inhibitors, adenosine diphosphate receptor antagonists, proton pump inhibitors, interleukin inhibitors, subtilisin/kexin type 9 proprotein convertase inhibitors, calcium reabsorption inhibitors, materials, medications, nutrition, therapy, orthopedic therapy. CM Hospitalar S/A was incorporated in 2010 and is headquartered in São Paulo, Brazil.

Company Details

  • SectorHealthcare
  • IndustryMedical Distribution
  • CEOAndré Clark Juliano
  • Employees6.00K
  • HeadquartersAv. Alfredo Egídio de Souza Aranha, São Paulo, SP, Brazil, 04726-170, Brazil
  • Websitehttps://ri.viveo.com.br

Leadership

  • André Clark JulianoCEO & Member of Management Board
  • Frederico de Aguiar OldaniMember of Management Board and VP of Administration & Finance
  • Flavia de Lima CarvalhoMember of Management Board & Director of Investor Relations and M&A
  • Renan de Almeida HervelhaCommercial Director & Member of Management Board
  • Mr. Luiz Augusto de Lima e Silva FilhoMember of Management Board & VP of Operations
  • Artur de Barros AvancineVice President of Capital Human & ESG and Member of Management Board

Financials

Income Statement

Currency: BRL2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.70B2.64B3.00B4.41B6.22B8.75B11.08B11.58B11.57B
Growth (%)-+55.75%+13.71%+46.96%+40.91%+40.65%+26.72%+4.51%-0.14%
Cost of Revenue1.49B2.24B2.53B3.77B5.13B7.35B9.35B10.28B9.90B
Gross Profit201.09M399.00M469.45M638.47M1.09B1.40B1.73B1.30B1.67B
Gross Margin11.86%15.11%15.63%14.47%17.52%15.97%15.64%11.27%14.43%
Operating Expense140.06M289.95M346.62M427.82M597.22M887.03M1.10B2.17B1.14B
Operating Income61.03M109.05M122.82M210.66M492.30M509.63M636.45M-862.99M531.66M
Operating Margin3.60%4.13%4.09%4.77%7.92%5.83%5.74%-7.45%4.60%
EBITDA88.00M164.25M120.13M309.59M615.26M721.12M1.06B-790.98M966.95M
EBITDA Margin5.19%6.22%4.00%7.01%9.89%8.24%9.56%-6.83%8.36%
Net Income58.78M34.09M35.75M121.77M395.15M259.73M359.92M-1.42B18.24M
Net Income Margin3.47%1.29%1.19%2.76%6.35%2.97%3.25%-12.22%0.16%
Interest Expense096.47M82.47M37.74M108.22M336.68M1.68M11.86M1.00M
Interest Expense % of Total Revenue0.00%3.65%2.75%0.86%1.74%3.85%0.02%0.10%0.01%

Balance Sheet

Currency: BRL2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.41B2.15B2.09B4.60B6.90B9.56B10.19B9.54B8.98B
Total Liabilities1.06B1.80B1.71B3.39B4.75B7.28B6.90B7.62B7.05B
Total Equity350.50M354.60M381.85M1.20B2.15B2.28B3.29B1.93B1.94B
Cash62.26M291.82M273.69M937.33M1.36B1.04B472.70M543.67M573.64M
Net Debt373.06M510.33M420.81M208.50M762.35M2.29B2.75B3.33B2.87B

Cash Flow

Currency: BRL2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow54.20M85.76M162.62M185.61M320.12M532.75M-895.63M34.15M276.58M
Investing Cash Flow-402.65M86.26M-18.69M-406.41M-1.42B-1.76B-179.57M-272.79M336.05M
Financing Cash Flow383.77M57.54M-162.06M884.44M1.52B903.90M505.34M309.61M-582.65M
Capital Expenditure3.28M27.82M20.53M49.36M77.95M152.24M376.16M185.29M165.53M
Free Cash Flow41.17M57.94M136.56M132.23M88.35M273.43M-1.20B-151.14M125.26M
Dividends Paid--45.00M45.00M45.00M45.00M74.74M43.48M-
FCF to OCF75.96%67.56%83.98%71.24%27.60%51.32%133.75%-442.57%45.29%
Dividend Paid to FCF--32.95%34.03%50.94%16.46%-6.24%-28.77%-

Earnings

Report DateNov 15, 2021Mar 9, 2022Aug 8, 2022Nov 10, 2022Mar 8, 2023May 11, 2023Aug 13, 2023Nov 13, 2023Mar 25, 2024May 9, 2024Aug 11, 2024Nov 13, 2024Mar 28, 2025May 13, 2025Aug 12, 2025Nov 10, 2025Dec 31, 2025May 14, 2026Aug 11, 2026
EPS Estimate0.280.180.180.170.210.230.210.240.040.06-0.05-0.04-0.16-0.10-0.11-0.14-0.16-0.18-0.13
EPS Actual0.300.320.190.220.320.130.230.210.850.04-0.02-0.18-0.13-0.07-0.140.13--0.11-0.07
Surprise7.14%77.78%5.56%29.41%52.38%-43.48%9.52%-12.50%2025.00%-33.33%60.00%-350.00%20.31%30.00%-27.27%192.86%-38.89%46.15%
TimingAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hours

Key Statistics & Ratios

Market Cap268.55M
Enterprise Value3.62B
Trailing P/E4.72
Forward P/E12.82
Price / Sales0.02
Price / Book0.14
EPS0.18
Book Value5.77
Revenue (TTM)11.71B
Gross Profit (TTM)1.79B
EBITDA653.49M
Profit Margin0.49%
Operating Margin4.68%
Return on Equity3.15%
Return on Assets4.27%
Shares Outstanding315.94M
Shares Float192.28M
Beta0.62
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20241×
0.14Apr 30, 2024
20222×
0.28Dec 27, 20220.16Apr 29, 2022
20211×
0.25Dec 28, 2021